NewAmsterdam Pharma Company N.V
NAMSW
Last
$11.00
Day
-6.5%
1y
+9.5%
5y
+1150.0%
52w
-63.9%
SPY YTD
+13.3%
Sec
—
Earnings
—
EMA 21
14.07
EMA 50
16.83
EMA 200
17.29
20d high
-38.9%
5y high
-63.9%
5y range
35th
Positions held
Your positionsNAMSW isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-35
Hold
avoid
Signal
Strong Sell
Target
$12.87
Stop
$9.44
Stop distance
14.2%
Target vs last
+17.0%
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | 2.36 | Beta | 0.10 | Dividend yield | — |
| Revenue growth | -80.7% | Earnings growth | — | Gross margin | 100.0% | Operating margin | -17.5% |
| Profit margin | 0.0% | ROE | -36.8% | ROA | -20.1% | Debt / equity | 0.00 |
| Current ratio | 9.03 | Free cash flow | -$45.36M | Analyst recommendation | none | Mean target | — |
| 52w high | $30.45 | 52w low | $10.41 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $3.7M | $3.0M | $0.0M | $0.3M | $19.1M | — |
| Op margin | -1752.6% | -1921.7% | -206187.5% | -15845.7% | -186.1% | — |
| Net income | -$64.1M | -$48.4M | -$74.9M | -$72.0M | -$17.4M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$64.9M | -$58.4M | -$66.0M | -$55.1M | -$35.6M | — |
- Revenue +22% vs prior quarter ($3.7M vs $3.0M).
- Operating margin expanded to -1752.6%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $22.5M | $45.6M | $14.1M | $103M | — |
| Op margin | -1002.9% | -386.9% | -1298.6% | -3.5% | — |
| Net income | -$204M | -$242M | -$177M | -$22.6M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$226M | -$176M | -$183M | -$3.6M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
No headlines.
Price (daily)
Full chart · RSI · MACD · patternsNAMSW · daily-23.8% over 11 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin